BRPI0203172B8 - composição farmacêutica para acondroplasia - Google Patents

composição farmacêutica para acondroplasia

Info

Publication number
BRPI0203172B8
BRPI0203172B8 BRPI0203172A BR0203172A BRPI0203172B8 BR PI0203172 B8 BRPI0203172 B8 BR PI0203172B8 BR PI0203172 A BRPI0203172 A BR PI0203172A BR 0203172 A BR0203172 A BR 0203172A BR PI0203172 B8 BRPI0203172 B8 BR PI0203172B8
Authority
BR
Brazil
Prior art keywords
achondroplasia
therapeutic agents
pharmaceutical composition
fgfr3
mutations
Prior art date
Application number
BRPI0203172A
Other languages
English (en)
Other versions
BR0203172A (pt
BRPI0203172B1 (pt
Inventor
Nakao Kazuwa
Original Assignee
Nakao Kazuwa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001301586A external-priority patent/JP2003104908A/ja
Priority claimed from JP2001310322A external-priority patent/JP4252746B2/ja
Application filed by Nakao Kazuwa filed Critical Nakao Kazuwa
Publication of BR0203172A publication Critical patent/BR0203172A/pt
Publication of BRPI0203172B1 publication Critical patent/BRPI0203172B1/pt
Publication of BRPI0203172B8 publication Critical patent/BRPI0203172B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Abstract

"agentes terapêuticos para acondroplasia". a presente invenção visa fornecer novos agentes terapêuticos para acondroplasia causada por mutações em fgfr3. são divulgados agentes terapêuticos para acondroplasia causada pela inibição de crescimento da cartilagem resultante de mutações no gene para o receptor do fator de crescimento de fibroblasto 3 (fgfr3), que compreende uma substância que ativa a guanilil ciclase b (gc-b) como um ingrediente ativo.
BRPI0203172A 2001-09-28 2002-08-13 composição farmacêutica para acondroplasia BRPI0203172B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001301586A JP2003104908A (ja) 2001-09-28 2001-09-28 軟骨無形成症治療剤
JP2001310322A JP4252746B2 (ja) 2001-10-05 2001-10-05 軟骨無形成症治療剤

Publications (3)

Publication Number Publication Date
BR0203172A BR0203172A (pt) 2003-09-09
BRPI0203172B1 BRPI0203172B1 (pt) 2016-02-23
BRPI0203172B8 true BRPI0203172B8 (pt) 2021-05-25

Family

ID=26623312

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0203172A BRPI0203172B8 (pt) 2001-09-28 2002-08-13 composição farmacêutica para acondroplasia

Country Status (3)

Country Link
US (2) US6743425B2 (pt)
BR (1) BRPI0203172B8 (pt)
CA (2) CA2398030C (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
EP3446711A1 (en) * 2004-03-31 2019-02-27 Kazuwa Nakao Composition for increasing body height
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
PL3404102T3 (pl) 2004-04-21 2021-12-13 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
ES2278519B1 (es) * 2005-09-02 2008-09-16 Fundacion Magar Tratamiento de la acondroplasia por la administracion de dinucleotidos.
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
MX2011012277A (es) * 2009-05-20 2011-12-12 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c.
WO2011153531A1 (en) 2010-06-04 2011-12-08 University Of South Florida Method of treating skeletal dysplasias using vessel dilator
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
ES2529369B2 (es) * 2013-07-09 2015-10-14 Ocupharm Diagnostics S.L. Uso del compuesto 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) para la elaboracion de un medicamento para el tratamiento de la acondroplasia
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
SG11201805026SA (en) 2016-01-08 2018-07-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
CA3007982C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
SG10202111952PA (en) * 2016-09-29 2021-12-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0478797T3 (da) 1990-04-20 1995-06-26 Hisayuki Matsuo Nyt fysiologisk aktivt peptid stammende fra gris
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
ATE290596T1 (de) * 1998-10-08 2005-03-15 Univ Hong Kong Verwendung transgener tiere, die eine mutation des collagen x enthalten
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias

Also Published As

Publication number Publication date
US6743425B2 (en) 2004-06-01
CA2398030A1 (en) 2003-03-28
US20040198665A1 (en) 2004-10-07
CA2918219A1 (en) 2003-03-28
CA2398030C (en) 2016-05-24
US20030068313A1 (en) 2003-04-10
BR0203172A (pt) 2003-09-09
BRPI0203172B1 (pt) 2016-02-23

Similar Documents

Publication Publication Date Title
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR0317591A (pt) Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
SI1532974T1 (sl) Zmes, ki vsebuje 6-(3-(1-adamantil)-4-metoksifenil)-2-naftensko kislino, za zdravljenje dermatoloških motenj
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
NZ527157A (en) Compositions for delivering bisphosphonates
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0210028A (pt) Agentes antibacterianos
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE9801495D0 (sv) Protein formulationa
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
ATE342264T1 (de) Indolderivate und deren verwendung als gnrh antagonisten
MXPA06003374A (es) Derivados de bencimidazolona y quinazolinona como agonistas en receptores semejantes al receptor opioide 1 de humano.
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/08/2022